VivoSeq
Oncology

Rectal Adenocarcinoma

25

Pipeline Programs↗

12

Active Trials↗

16

Companies Involved↗

Rectal Adenocarcinoma is an emerging landscape with 25 programs across 16 companies. The most active players are Eisai, Astellas, Peregrine Pharmaceuticals. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

15/100

Mech. Concentration

30/100

Completion Rate

33/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1P

Peregrine Pharmaceuticals

1 program

Phase 1Teva logo

Teva

1 program

Phase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 2Arcus Biosciences logo

Arcus Biosciences

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

21 of 30 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody930%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.

Analysis

Trial Status

26

clinical trials

Recruiting9 · 35%
Unknown status5 · 19%
Terminated4 · 15%
Completed3 · 12%
Active, not recruiting3 · 12%
Withdrawn2 · 8%

Clinical Trials

Trial Activity

26 trials

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06843434·40 enrolled
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06266832·30 enrolled
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Recruiting·—·Phase 1·NCT07104604·59 enrolled
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06569368·60 enrolled
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Recruiting·SSir Run Run Shaw Hospital·Phase 3·NCT05752136·108 enrolled
Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Prospective, Multicenter Phase II Study(CRIT)
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT06908031·49 enrolled
Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Phase III Randomized Controlled Trial
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT07549399·204 enrolled
Phase II Clinical Trial of FOLFOX, Botensilimab, Plus Balstilimab in Patients With Localized Rectal Cancer
Recruiting·CCity of Hope Medical Center·Phase 2·NCT06780787·26 enrolled
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT07669220·76 enrolled
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05108428·20 enrolled
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
Active, not recruiting·CCentre Antoine Lacassagne·Phase 3·NCT02505750·148 enrolled
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
Active, not recruiting·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT07127497·50 enrolled
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02935309·20 enrolled
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT01634685·15 enrolled
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)
Completed·SSir Run Run Shaw Hospital·Phase 2·NCT05216653·32 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)